All In Biotech

NDA 021394 · Haleon US Holdings

Advil Pm

Diphenhydramine Citrate, Ibuprofen · Oral · Nonsteroidal Anti-inflammatory Drug

Last checked: Nov 20, 2026Latest source record: Feb 21, 2023 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2005

Dec 21, 2005

Approved uses

1

Original approval plus efficacy supplements

Registered trials

1,141

246 Phase 3, 67 recruiting

FAERS reports

4,783

777 serious, 42 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect May 27, 2026.

Uses for relief of occasional sleeplessness when associated with minor aches and pains helps you fall asleep and stay asleep

Therapeutic areas: Pain and anesthesia

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

1 products under this application
  • ADVIL PM · DIPHENHYDRAMINE CITRATE 38MG; IBUPROFEN 200MG · TABLET, ORAL · Over-the-counter

Clinical trials

Interventional ClinicalTrials.gov studies with "Diphenhydramine" as an intervention, any sponsor and status, largest first.

All 1,141 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • drug ineffective1,234
  • somnolence456
  • product use in unapproved indication346
  • drug effective for unapproved indication284
  • insomnia256
  • feeling abnormal230
  • dizziness197
  • fatigue195
  • intentional product misuse145
  • overdose131
  • headache121
  • nausea114

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
200638
2007123
200856
200927
2010390
2011239
2012263
2013309
2014331
2015423
2016506
2017355
2018442
2019177
2020218
2021577
2022155
202360
202435
202531
202628

Recalls

1 FDA enforcement reports for this application.

  • Feb 26, 2014 · Class III · Terminated

    Subpotent Drug: This lot is being recalled because of out-of-specification test results for Diphenhydramine citrate.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 557 on PubMed

Sponsor: Haleon US Holdings

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.